Levosimendan in Sepsis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Effect of levosimendan on mortality in severe sepsis and septic shock: a meta-analysis of randomised trials.BMJ open · 2018
   Pooled it
2. Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial.Intensive care medicine · 2019
   Trial
3. Levosimendan in intensive care and emergency medicine: literature update and expert recommendations for optimal efficacy and safety.Journal of anesthesia, analgesia and critical care · 2022
   Review
4. Early Vitamin C, Hydrocortisone, and Thiamine Treatment for Septic Cardiomyopathy: A Propensity Score Analysis.Journal of personalized medicine · 2021
   Article
5. Inodilators in septic shock: should these be used?Annals of translational medicine · 2020
   Review

Corrections and comments

• Commented on by
  Levosimendan in Sepsis.2017
• Comment on
  Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis.2016

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as